Other languages Teva Pharmaceutical Industries Ltd (ADR) Nasdaq

Equities

US8816242098

Real-time Estimate Cboe BZX Other stock markets 12:11:51 16/05/2024 BST			5-day change	1st Jan Change
16.9 ^USD	0.00%		0.00%	0.00%

05-15	Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	MT
05-15	Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	05-15
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024	05-15
En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...	05-09
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	05-08
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed	05-08
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	05-08
Sector Update: Health Care	05-08
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	05-08
Teva Pharm Q1 profit falls short of estimates, revenue gains	05-08
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024	05-08
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	05-01
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	04-30
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	04-30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	04-30
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	04-30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	04-30
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	04-30
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	04-17
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	04-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 09:41 am

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 08:19 pm